Yasemin Sanli1, Serkan Kuyumcu2, Oner Sanli3, Fikret Buyukkaya4, Ayça İribaş5, Goksel Alcin2, Emin Darendeliler5, Yasemin Ozluk6, Sevda Ozel Yildiz7, Cüneyt Turkmen2. 1. Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Ic Hastalıkları Binasi, Nukleer Tip Anabilim Dali, Istanbul, Turkey. yaseminsanli75@yahoo.com. 2. Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Ic Hastalıkları Binasi, Nukleer Tip Anabilim Dali, Istanbul, Turkey. 3. Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 4. Faculty of Health Science, Istanbul University, Istanbul, Turkey. 5. Department of Radiation Oncology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 6. Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 7. Department of Biostatistics and Medical Informatics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Abstract
AIM: To investigate the relationship between serum PSA level, Gleason score of PCa and the outcomes of Ga68-PSMA PET/CT in patients with recurrent PCa. METHODS: A total of 109 consecutive patients (median age 71 years; range 48-89 years) who had PSA recurrence after RP and/or hormonotherapy and/or radiotherapy were included in this study. Local recurrences, lymph node metastasis (pelvic, abdominal and/or supradiaphragmatic), bone metastases (oligometastatic/multimetastatic) and other metastatic sites (lung, liver, brain, etc) were documented. RESULTS: In 91(83.4%) patients at least one lesion characteristic for PCa was detected by68Ga-PSMA PET/CT. The median serum total PSA (tPSA) was 6.5 (0.2-640) ng/ml.There was a significant difference between 68Ga-PSMA PET/CT positive and negative patients in terms of serum total PSA value. No statistical significance was found between positive and negative 68Ga-PSMA PET/CT findings in terms of Gleason score. Local recurrence was detected in 56 patients. whereas lymph node metastases were demonstrated in 46 patients. Pelvic nodal disease was the most frequent presentation followed by abdominal and supradiaphragmaticnodal involvement. Bone metastases [oligometastasis, (n = 20); multimetastasis, (n = 35)⦌ were also detected in 55 patients. In the ROC analysis for the study cohort, the optimal cut-off value of total serum PSA was determined as 0.67 ng/ml for distinguishing between positive and negative 68Ga-PSMA PET/CT images, with an area under curve of 0.952 (95% CI 0.911-0.993). CONCLUSIONS: 68Ga-PSMA PET/CT was found to be an effective tool for the detection of recurrent PCa. Even though no relationship was detected between the GS and 68Ga-PSMA PET/CT findings, serum total PSA values may be used for estimating the likelihood of positive 68Ga-PSMA PET/CT results.
AIM: To investigate the relationship between serum PSA level, Gleason score of PCa and the outcomes of Ga68-PSMA PET/CT in patients with recurrent PCa. METHODS: A total of 109 consecutive patients (median age 71 years; range 48-89 years) who had PSA recurrence after RP and/or hormonotherapy and/or radiotherapy were included in this study. Local recurrences, lymph node metastasis (pelvic, abdominal and/or supradiaphragmatic), bone metastases (oligometastatic/multimetastatic) and other metastatic sites (lung, liver, brain, etc) were documented. RESULTS: In 91(83.4%) patients at least one lesion characteristic for PCa was detected by68Ga-PSMA PET/CT. The median serum total PSA (tPSA) was 6.5 (0.2-640) ng/ml.There was a significant difference between 68Ga-PSMA PET/CT positive and negative patients in terms of serum total PSA value. No statistical significance was found between positive and negative 68Ga-PSMA PET/CT findings in terms of Gleason score. Local recurrence was detected in 56 patients. whereas lymph node metastases were demonstrated in 46 patients. Pelvic nodal disease was the most frequent presentation followed by abdominal and supradiaphragmaticnodal involvement. Bone metastases [oligometastasis, (n = 20); multimetastasis, (n = 35)⦌ were also detected in 55 patients. In the ROC analysis for the study cohort, the optimal cut-off value of total serum PSA was determined as 0.67 ng/ml for distinguishing between positive and negative 68Ga-PSMA PET/CT images, with an area under curve of 0.952 (95% CI 0.911-0.993). CONCLUSIONS: 68Ga-PSMA PET/CT was found to be an effective tool for the detection of recurrent PCa. Even though no relationship was detected between the GS and 68Ga-PSMA PET/CT findings, serum total PSA values may be used for estimating the likelihood of positive 68Ga-PSMA PET/CT results.
Entities:
Keywords:
68Ga-PSMA; Gleason score; PSA value; Recurrent prostate cancer
Authors: Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll Journal: J Nucl Med Date: 2018-12-07 Impact factor: 10.057
Authors: Daniel Walacides; Astrid Meier; Anne Caroline Knöchelmann; Daniele Meinecke; Thorsten Derlin; Frank M Bengel; Tobias L Ross; Hans-Jürgen Wester; Katja Derlin; Markus A Kuczyk; Christoph A J von Klot; Hans Christiansen; Christoph Henkenberens Journal: Strahlenther Onkol Date: 2019-01-04 Impact factor: 3.621
Authors: Felipe Couñago; Claudio Martínez-Ballesteros; Carlos Artigas; Ana Aurora Díaz-Gavela; Luis Leonardo Guerrero Gómez; María Eugenia Lillo-García; José Reinaldo Chicharo; Manuel Recio; Antonio Maldonado; Israel J Thuissard; Cristina Andreu-Vázquez; David Sanz-Rosa; Antonio José Conde-Moreno; Francisco José Marcos; Sofía Sánchez García; Juan Ignacio Martínez-Salamanca; Joaquin Carballido-Rodríguez; Javier Hornedo; Elia Del Cerro Journal: Rep Pract Oncol Radiother Date: 2020-04-12
Authors: K Schiller; M Devecka; T Maurer; M Eiber; J Gschwend; M Schwaiger; S E Combs; G Habl Journal: Radiat Oncol Date: 2018-03-01 Impact factor: 3.481
Authors: Henk B Luiting; Pim J van Leeuwen; Martijn B Busstra; Tessa Brabander; Henk G van der Poel; Maarten L Donswijk; André N Vis; Louise Emmett; Phillip D Stricker; Monique J Roobol Journal: BJU Int Date: 2019-11-29 Impact factor: 5.588